B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

Scott E. Strome, Haidong Dong, Hideto Tamura, Stephen G. Voss, Dallas B. Flies, Koji Tamada, Diva Salomao, John Cheville, Fumiya Hirano, Wei Lin, Jan L. Kasperbauer, Karla V. Ballman, Lieping Chen

Research output: Contribution to journalArticle

Abstract

In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.

Original languageEnglish (US)
Pages (from-to)6501-6505
Number of pages5
JournalCancer Research
Volume63
Issue number19
StatePublished - Oct 1 2003
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomao, D., Cheville, J., Hirano, F., Lin, W., Kasperbauer, J. L., Ballman, K. V., & Chen, L. (2003). B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Research, 63(19), 6501-6505.